All News

Poziotinib demonstrates positive results for treatment-naïve patients with non-small cell lung cancer harboring HER2 exon 20 insertion mutations.

Ivosidenib in combination with azacitidine found to significantly improve event-free survival in patients with previously untreated IDH1-mutated acute myeloid leukemia.

Empagliflozin and linagliptin (Glyxambi) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

OTC severe sinus medications offer relief to sinus headaches, help to loosen phlegm, reduces sinus pressure and chest congestions, and temporarily reduces fever

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the adverse events patients with ovarian cancer have reported during treatment with rucaparib.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how oncology pharmacy professionals can effectively address fatalistic beliefs and perceptions of cancer-related information among rural adults.

Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

Novel C. difficile infection (CDI) vaccine shows promise lowering the severity of CDI and in preventing medically attended CDI.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.

Researchers found that in a program of biennial screening of women aged 50 to 74 years, approximately 1 in 7 screen-detected breast cancer cases would be overdiagnosed.

Study results show immunoglobulin G antibodies were detected in 13 of 382 individuals in the first phase and 71 of 168 in the second, with age and vaccination status contributing factors.

The proof-of-concept study is expected to announce topline safety, tolerability, and immunogenicity results by the end of 2022.

The annual conference includes presentations with educational opportunities related to community pharmacies, health system pharmacies, pharmacy law, public health, and more.

Nivolumab (Opdivo) plus platinum-doublet chemotherapy approved for the treatment of adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Study results show that individuals hospitalized for acute heart failure are 36% more likely to experience clinical benefit over 90 days if initiated on the drug following stabilization.

The findings highlight the potential of acetaminophen, non-steroidal anti-inflammatory drugs, and opioid analgesics to treat infectious diseases.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses the treatments for hypoactive sexual desire disorder currently available and those not yet approved.

David Drapkin, director of operations and strategic growth at Psychedelics Today, discussed the new Diversity, Equity, and Inclusion Training Fund for clinicians and practitioners in psychedelic medicine.

Durvalumab plus chemotherapy did not increase the discontinuation rate due to adverse events compared to chemotherapy alone.

In episode 7 of Coffee With Suzy, Suzanne Soliman, PharmD, BCMAS, spoke with ChiChi Illonzo Momah, PharmD, RPh, about women in pharmacy ownership.

Kaléo’s product has received fast-track designation for US military personnel facing this threat on the battlefield.

Durable responses mark a significant advancement over chemotherapy, which may have only been effective for 9 to 10 months.

Study findings support the role of tezepelumab-ekko as a first-in-class treatment for a broad population of patients living with severe asthma, irrespective of biomarker levels.

Acceptance is based on CheckMate -816 trial results where the agency granted priority review status to the Bristol Myers Squibb drug and assigned a PDUFA goal date of July 13, 2022.

Investigators at Penn State find that these medications inhibit certain viral enzymes called proteases that are essential for SARS-CoV-2 replication in infected human cells.

COVID-19 vaccines are effective in preventing severe infection resulting in hospitalization, but protection wanes after 6 months.

There are a few options that can help with the current mental health epidemic, although more studies are recommended to perfect these treatments.

New strategies are needed to increase HIV prevention and testing efforts among high-risk communities.